estrogen metabolite ratio : Is the 2-hydroxyestrone to 16 α-hydroxyestrone ratio predictive for breast cancer ?

Correspondence: Nadia Obi Department of Cancer epidemiology/ Clinical Cancer Registry, University Cancer Center Hamburg (UCCH)/ Hubertus Wald Tumor Center, University Medical Center Hamburg-eppendorf, Martinistr. 52, 20246 Hamburg, Germany Tel +49 40 7410 59525 Fax +49 40 7410 57934 email n.obi@uke.de Abstract: Experimental studies have shown that two main estrogen metabolites hydroxylated by CYP1A1 and CYP1B1 in the breast differentially affect breast cell proliferation and carcinogenesis. Although 16α-hydroxyestrone (16αOHE1) exerts estrogenic activity through covalent estrogen receptor (ER) binding, 2-hydroxyestrone (2OHE1) presumably has antiestrogenic capabilities. The ratio of 2OHE1 to 16αOHE1 represents the relative dominance of one pathway over the other and is believed to be modifiable by diet. It was hypothesized that women with or at high risk of breast cancer have a lower estrogen metabolite ratio (EMR) compared with women without breast cancer. We conducted a systematic review on the EMR as a predictor for breast cancer. A total of nine studies (six prospective and three retrospective) matched our inclusion criteria, comprising 682 premenopausal cases (1027 controls) and 1189 postmenopausal cases (1888 controls). For the highest compared with the lowest quantile of urinary EMR, nonsignificant associations suggested at best a weak protective effect in premenopausal but not in postmenopausal breast cancer (range of odds ratios: 0.50–0.75 for premenopausal and 0.71–1.31 for postmenopausal). Circulating serum/plasma EMR was not associated with breast cancer risk. Associations were inconclusive for receptor subtypes of breast cancer. Uncontrolled factors known to be involved in breast carcinogenesis, such as 4-hydroxyestrone (4OHE1) concentration, may have confounded results for EMR. Results of the prospective studies do not support the hypothesis that EMR can be used as a predictive marker for breast cancer risk. Future research should concentrate on profiles of estrogen metabolites, including 4OHE1, to gain a more complete picture of the relative importance of single metabolites for breast cancer.

[1]  E. Taioli,et al.  Urinary 2/16 estrogen metabolite ratio levels in healthy women: a review of the literature. , 2010, Mutation research.

[2]  T. Veenstra,et al.  Comparison of estrogens and estrogen metabolites in human breast tissue and urine , 2010, Reproductive biology and endocrinology : RB&E.

[3]  R. Hoover,et al.  Comparison of Liquid Chromatography-Tandem Mass Spectrometry, RIA, and ELISA Methods for Measurement of Urinary Estrogens , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  R. Hoover,et al.  Soy Intake is Associated with Increased 2-Hydroxylation and Decreased 16α-Hydroxylation of Estrogens in Asian-American Women , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[5]  E. Taioli,et al.  Urinary estrogen metabolites in women at high risk for breast cancer. , 2009, Carcinogenesis.

[6]  R. Shore,et al.  Circulating Estrogen Metabolites and Risk for Breast Cancer in Premenopausal Women , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[7]  V. Konovalova,et al.  IMPACT OF HORMONE REPLACEMENT THERAPY ON ENDOGENOUS ESTRADIOL HYDROXYMETABOLISM IN RUSSIAN POSTMENOPAUSAL WOMEN , 2009 .

[8]  G. Wong,et al.  Lycium Barbarum Inhibits Growth of Estrogen Receptor Positive Human Breast Cancer Cells by Favorably Altering Estradiol Metabolism , 2009, Nutrition and cancer.

[9]  T. Byers,et al.  Ethnicity, body size, and estrogen levels in postmenopausal Hispanic and non-Hispanic white women. , 2009, Journal of women's health.

[10]  S. Hankinson,et al.  Circulating 2-Hydroxy- and 16α-Hydroxy Estrone Levels and Risk of Breast Cancer among Postmenopausal Women , 2008, Cancer Epidemiology Biomarkers & Prevention.

[11]  Wendy Y Chen.  Exogenous and endogenous hormones and breast cancer. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[12]  J. Meza,et al.  The molecular etiology of breast cancer: Evidence from biomarkers of risk , 2007, International journal of cancer.

[13]  M. Kibriya,et al.  Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer , 2007, Breast Cancer Research and Treatment.

[14]  Graham A Colditz,et al.  Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. , 2006, Journal of the National Cancer Institute.

[15]  I. Gram,et al.  Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. , 2006, American journal of epidemiology.

[16]  D. Spiegelman,et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.

[17]  P. Muti,et al.  Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. , 2006, Biochimica et biophysica acta.

[18]  S. Crawford,et al.  Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. , 2006, The Journal of nutrition.

[19]  J. Russo,et al.  Estradiol and its metabolites 4‐hydroxyestradiol and 2‐hydroxyestradiol induce mutations in human breast epithelial cells , 2006, International journal of cancer.

[20]  T. Klug,et al.  Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer , 2006, International journal of cancer.

[21]  T. Saleh,et al.  Role of Polymorphic Human Cytochrome P450 Enzymes in Estrone Oxidation , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  T. Klug,et al.  Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites. , 2006, Molecular genetics and metabolism.

[23]  A. Tjønneland,et al.  Urinary Hydroxyestrogens and Breast Cancer Risk among Postmenopausal Women: A Prospective Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[24]  E. Taioli,et al.  A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio , 2005, Clinical chemistry and laboratory medicine.

[25]  M. Pike,et al.  Urinary estrogen metabolites and their ratio among Asian American women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  M. García-Closas,et al.  Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  C. Guillemette,et al.  Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview , 2004, Breast Cancer Research.

[28]  X. Shu,et al.  Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. , 2004, Cancer Epidemiology, Biomarkers and Prevention.

[29]  C. Ulrich,et al.  Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women , 2004, Cancer Epidemiology Biomarkers & Prevention.

[30]  S. Cummings,et al.  Estrogen Metabolites and the Risk of Breast Cancer in Older Women , 2003, Epidemiology.

[31]  A. Hirvonen,et al.  Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. , 2003, Mutation research.

[32]  A. Conney,et al.  Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. , 2003, Endocrinology.

[33]  T. Key,et al.  Oestrogen exposure and breast cancer risk , 2003, Breast Cancer Research.

[34]  D. Axelrod,et al.  Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[35]  T. Klug,et al.  Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. , 2003, Carcinogenesis.

[36]  Jane L Meza,et al.  Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. , 2003, Carcinogenesis.

[37]  X. Shu,et al.  Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection , 2003, Steroids.

[38]  G. Carruba,et al.  Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[40]  M. Pike,et al.  Urinary 2-Hydroxyestrone/16α-Hydroxyestrone Ratio and Family History of Breast Cancer in Premenopausal Women , 2002, Breast Cancer Research and Treatment.

[41]  A. Linos,et al.  Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[42]  B. Henderson,et al.  Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? , 2001, Cancer research.

[43]  F. Berrino,et al.  Estrogen Metabolism and Risk of Breast Cancer: a Prospective Study of the 2:16␣-hydroxyestrone Ratio in Premenopausal and Postmenopausal Women , 2022 .

[44]  M. García-Closas,et al.  Factors critical to the design and execution of epidemiologic studies and description of an innovative technology to follow the progression from normal to cancer tissue. , 2000, Journal of the National Cancer Institute. Monographs.

[45]  J. Holtzman,et al.  Within-person variability of the ratios of urinary 2-hydroxyestrone to 16α-hydroxyestrone in Caucasian women☆ , 1999, Steroids.

[46]  J. Manson,et al.  Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  A. Duncan,et al.  Menstrual cycle effects on urinary estrogen metabolites. , 1999, The Journal of clinical endocrinology and metabolism.

[48]  M. Pike,et al.  Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. , 1999, Journal of the National Cancer Institute.

[49]  K. Westerlind,et al.  The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: Implications for disease-risk assessment , 1999, Steroids.

[50]  L. Kuller,et al.  Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. , 1998, British Journal of Cancer.

[51]  T. Klug,et al.  Application of an improved ELISA assay to the analysis of urinary estrogen metabolites , 1998, Steroids.

[52]  G. Ho,et al.  Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. , 1998, Annals of the Academy of Medicine, Singapore.

[53]  J. Rodriguez-Sierra,et al.  Re: ethnic differences in estrogen metabolism in healthy women. , 1997, Journal of the National Cancer Institute.

[54]  J. Sparano,et al.  Urinary estrogen metabolites and breast cancer: a case-control study. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[55]  M. Katdare,et al.  Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. , 1997, Environmental health perspectives.

[56]  R. Hoover,et al.  Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. , 1997, Environmental health perspectives.

[57]  M. Osborne,et al.  2-hydroxyestrone: the 'good' estrogen. , 1996, The Journal of endocrinology.

[58]  J. Dwyer,et al.  Estrogen metabolism and excretion in Oriental and Caucasian women. , 1994, Journal of the National Cancer Institute.

[59]  M. Osborne,et al.  Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. , 1993, Journal of the National Cancer Institute.

[60]  M. Osborne,et al.  Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells , 1993, Breast Cancer Research and Treatment.

[61]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[62]  H. Bradlow,et al.  Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K. Anderson,et al.  Abnormal oxidative metabolism of estradiol in women with breast cancer. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. Cavalieri,et al.  Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. , 2010, Future oncology.

[65]  J. Chang-Claude,et al.  Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). , 2005, Journal of the National Cancer Institute.

[66]  M. Martini,et al.  Effects of soy intake on sex hormone metabolism in premenopausal women. , 1999, Nutrition and cancer.

[67]  S. Safe,et al.  Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. , 1998, The Journal of steroid biochemistry and molecular biology.

[68]  L. Kuller,et al.  Urinary markers of estrogen metabolism 2- and 16 alpha-hydroxylation in premenopausal women. , 1996, Steroids.

[69]  E. Taioli,et al.  Ethnic differences in estrogen metabolism in healthy women. , 1996, Journal of the National Cancer Institute.

[70]  T. Klug,et al.  Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine. , 1994, Steroids.

[71]  H. Adlercreutz,et al.  Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. , 1989, Journal of steroid biochemistry.

[72]  H. Bradlow,et al.  16 alpha-hydroxylation of estradiol: a possible risk marker for breast cancer. , 1986, Annals of the New York Academy of Sciences.

[73]  J. Liehr,et al.  Carcinogenicity of catechol estrogens in Syrian hamsters. , 1986, Journal of steroid biochemistry.

[74]  H. Bradlow,et al.  Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. , 1984, Journal of steroid biochemistry.